GET DAILY SIGNALSCentene (CNC) vs Molina (MOH): Margin Recovery Momentum in Managed Care
Key Takeaways
- CNC is executing a faster margin recovery, with management raising full-year adjusted EPS guidance after a strong earnings beat, while MOH is earlier in its turnaround and still absorbing Medicaid margin pressure.
- Centene's shares have delivered substantially stronger relative performance over the past year, while Molina's rebound has been more modest and remains tied to a Medicaid rate cycle that is only beginning to turn.
- Tickeron AI Verdict: Based on trend consistency, relative momentum, and margin-improvement catalysts, Tickeron's AI currently favors CNC over MOH.
- Both companies are heavily exposed to government-sponsored health programs, so Medicaid reimbursement rates, membership shifts, and regulatory policy are shared risk factors for each stock.
- For more detail, explore CNC Major News and CNC Today's Price Move, as well as MOH Major News and MOH Today's Price Move.
- To see how AI-powered systems are trading these and other tickers, visit Trending AI Robots.
Background on These Two Managed Care Operators
CNC (Centene Corporation) and MOH (Molina Healthcare) rank among the largest managed care organizations in the United States. Both focus primarily on government-sponsored health plans such as Medicaid, Medicare, and Affordable Care Act (ACA) Marketplace coverage. Because they operate in the same sector and encounter similar regulatory and reimbursement pressures, comparing the two provides a useful perspective on how similar businesses can differ in momentum and execution. This comparison matters for investors tracking the managed care recovery, where margin trends, membership shifts, and state rate cycles influence sentiment and relative performance. I also checked this using Tickeron’s AI Screener to see how the stocks compare within the industry.
Centene's Recent Progress and Results
Centene Corporation is one of the nation's largest managed care providers, serving members across Medicaid, Medicare, and Marketplace segments. In recent weeks, Centene has reinforced its position as a turnaround story. The company's latest quarterly results exceeded expectations, with revenue growth and adjusted earnings per share (EPS) well above consensus, driven by strength in its Medicare and Marketplace businesses and disciplined cost management in Medicaid. Management raised its full-year adjusted EPS guidance and signaled that Medicare Advantage reached financial breakeven ahead of schedule. This progress follows a challenging period in which Centene withdrew guidance amid higher medical costs, so the recent recovery reflects improved pricing, better medical cost trends, and tighter operational controls. Over the past year, the stock has delivered a significant rally, and it now trades near the upper end of its 52-week range. Sentiment has shifted from concern over medical cost trends toward optimism about margin recovery, though membership attrition in Medicaid remains a key watch item. From what I see, the upward guidance revision stands out as a positive signal.
Molina's Current Position and Challenges
Molina Healthcare provides managed care services primarily to low-income individuals and families through Medicaid, Medicare, and Marketplace programs. Its recent market activity reflects a company still working through elevated medical costs. Recent quarterly results beat consensus on both revenue and adjusted EPS, and management reaffirmed full-year guidance, pointing to early signs that Medicaid margins are stabilizing after a multi-year downturn. Unlike Centene, Molina's revenue and membership have been declining on a year-over-year basis as it reduces its Marketplace footprint and exits underperforming Medicare Advantage (MAPD) products. The company is positioning itself around its Medicaid dual-eligible (duals) business and newly won state contracts, including a large Florida contract, which management expects to contribute meaningfully to earnings in 2027 and beyond. Molina's shares have rebounded in recent weeks, but the stock's forward valuation remains elevated relative to its current earnings, reflecting the market's anticipation of a recovery that has not yet fully materialized. I’m watching this closely because the timing of those contract contributions adds an extra layer of uncertainty.
Head-to-Head Comparison
While Centene and Molina compete in similar government-sponsored markets, their current positioning differs in important ways. Centene is a larger, more diversified operator with a market capitalization roughly three times Molina's, and it is further along in its margin recovery. Its Medicare Advantage business has reached breakeven ahead of plan, and its Marketplace segment is generating improving margins. Centene also trades at a relatively modest forward price-to-earnings multiple, supported by analysts' consensus "Buy" rating. Molina, by contrast, is more concentrated in Medicaid and is deliberately shrinking its Marketplace and general Medicare Advantage exposure to focus on higher-return dual-eligible products and newly won contracts. Its growth narrative rests heavily on a 2027 Medicaid rate cycle and the ramp-up of recent contract wins, which introduces more execution and timing risk in the near term. Both stocks share sector-level risks, including federal and state reimbursement decisions, membership attrition from eligibility reviews and work requirements, and medical cost inflation, but Centene's demonstrated momentum and earlier-stage margin expansion give it a clearer near-term trajectory.
AI Assessment and Outlook
Based on observable factors such as trend consistency, relative momentum, margin-improvement catalysts, and valuation positioning, Tickeron's AI would likely favor CNC over MOH in the current environment. Centene's stronger recent price performance, earlier achievement of breakeven in Medicare Advantage, and upward guidance revisions indicate more established trend strength, whereas Molina's recovery remains more dependent on future rate cycles and contract execution. This probabilistic assessment reflects the balance of current data rather than a definitive prediction of future returns.
Using AI Tools for Deeper Analysis
In my own research process, I often turn to Tickeron’s AI Trading Bots to test how different automated strategies perform across market conditions. These systems cover thousands of tickers with varying styles, timeframes, and performance records, allowing me to compare approaches that align with my objectives. One resource I find particularly useful is the curated selection of strategies positioned for current conditions, which helps put the relative momentum between names like CNC and MOH into perspective without replacing my own judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MOH in upward trend: 10-day moving average broke above 50-day moving average on October 15, 2026
The 10-day moving average for MOH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
MOH moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in 210 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 148 of 222 cases where MOH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for MOH moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 20 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 59%.
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MOH as a result. In 60 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for MOH turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 32 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
MOH broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 33 (best 1 - 100 worst), indicating outstanding price growth. MOH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.563) is normal, around the industry mean (3.380). MOH's P/E Ratio (1279.875) is considerably higher than the industry average of (124.266). Projected Growth (PEG Ratio) (0.880) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.233) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of health care services to persons eligible for Medicaid
Industry ManagedHealthCare
Advertisement